Results 211 to 220 of about 484,958 (335)

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. [PDF]

Psychopharmacology (Berl), 2018
Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT.   +11 more
europepmc   +1 more source

Arginine Metabolism and Adenosine Receptor Signals in the Cerebellum Contribute to Nicotine Withdrawal‐Induced Anxiety/Depression‐Like Behaviours

Addiction Biology, Volume 30, Issue 8, August 2025.
This research indicates that enhanced purine metabolism and disrupted arginine metabolism contribute to the nicotine withdrawal‐induced anxiety and depression‐like behaviours in the cerebellum. Treatment with theobromine markedly alleviates these behaviours.
Wenjuan Zhang, Yu Tian, Xiao Yang, Baojiang He, Haifeng Zhang, Qi Zhang, Yingwu Mei   +6 more
wiley   +1 more source

Evaluation of Agonist and Antagonist Activities against Nicotinic Acetyicholine Receptors

, 2002
Kazuhiko Matsuda
openalex   +2 more sources

Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors [PDF]

, 2007
Jeremy G. Richman, Martha Kanemitsu-Parks, Ibragim Gaidarov, Jill S. Cameron, Peter S. Griffin, Hong Zheng, Nuvia C. Guerra, Linda Cham, Dominique Maciejewski-Lenoir, Dominic P. Behan, Doug Boatman, Ruoping Chen, Philip J. Skinner, Pricilla Ornelas, M. Gerard Waters, Samuel D. Wright, Graeme Semple, Daniel T. Connolly   +17 more
openalex   +1 more source

Levodopa and Plant‐Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives

CNS Neuroscience &Therapeutics, Volume 31, Issue 8, August 2025.
Plant‐derived compounds such as polyphenols, flavonoids, alkaloids, and terpenoids exhibit neuroprotective, antioxidant, and anti‐inflammatory activities in Parkinson's disease models. Unlike levodopa, they provide disease‐modifying benefits by targeting α‐synuclein aggregation, mitochondrial dysfunction, and neuroinflammation.
Emre Aktaş, Haşmet Ayhan Hanağası, Nehir Özdemir Özgentürk   +2 more
wiley   +1 more source

A structural model of agonist binding to the α3β4 neuronal nicotinic receptor

, 2003
Valéria Catelli Infantozzi Costa, Andrea Nistri, Andrea Cavalli, Paolo Carloni   +3 more
openalex   +1 more source

Nicotinic α5 subunit deletion locally reduces high‐affinity agonist activation without altering nicotinic receptor numbers [PDF]

, 2007
R.W. Brown, Allan C. Collins, Jon Lindstrom, Paul Whiteaker   +3 more
openalex   +1 more source

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Cell Proliferation, Volume 58, Issue 8, August 2025.
Polymeric nanoparticles represent promising drug (gene) delivery carriers to the brain due to their unique advantages to facilitate the penetration of blood–brain barrier and endocytosis of neuronal cells in neurodegenerative diseases. ABSTRACT In spite of great advances in modern medicine, there are a few effective strategies for the treatment of ...
Lian Jin, Libo Nie, Yan Deng, Ghulam Jilany Khana, Nongyue He   +4 more
wiley   +1 more source

Volatile Anesthetics Reduce Agonist Affinity at Nicotinic Acetylcholine Receptors in the Brain

, 2003
Erin M. Rada, Elizabeth C. Tharakan, Pamela Flood   +2 more
openalex   +1 more source

Antilipolytic Activity of a Novel Partial A₁Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic Acid [PDF]

, 2007
Arvinder K. Dhalla, Melissa Santikul, Michelle G. Smith, Mei-Yee Wong, John C. Shryock, Luiz Belardinelli   +5 more
openalex   +1 more source